Fundamental Analysis of UROGEN PHARMA LTD(NASDAQ:URGN) stock

Fundamental Rating

Overall URGN gets a fundamental rating of 3 out of 10. We evaluated URGN against 576 industry peers in the Biotechnology industry. Both the profitability and financial health of URGN have multiple concerns. URGN is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year URGN has reported negative net income.

In the past year URGN has reported a negative cash flow from operations.

URGN had negative earnings in each of the past 5 years.

URGN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -52.01%, URGN is in line with its industry, outperforming 46.07% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-52.01%
ROE	N/A
ROIC	N/A

ROA(3y)-76.96%

ROA(5y)-77.63%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

URGN's Gross Margin of 89.54% is amongst the best of the industry. URGN outperforms 92.50% of its industry peers.

URGN's Gross Margin has been stable in the last couple of years.

URGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	89.54%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.02%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

URGN does not have a ROIC to compare to the WACC, probably because it is not profitable.

URGN has more shares outstanding than it did 1 year ago.

The number of shares outstanding for URGN has been increased compared to 5 years ago.

Compared to 1 year ago, URGN has an improved debt to assets ratio.

2.2 Solvency

URGN has an Altman-Z score of -3.13. This is a bad value and indicates that URGN is not financially healthy and even has some risk of bankruptcy.

URGN has a Altman-Z score (-3.13) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.13

ROIC/WACCN/A

WACC8.68%

2.3 Liquidity

A Current Ratio of 7.47 indicates that URGN has no problem at all paying its short term obligations.

URGN has a better Current ratio (7.47) than 68.06% of its industry peers.

URGN has a Quick Ratio of 7.20. This indicates that URGN is financially healthy and has no problem in meeting its short term obligations.

URGN's Quick ratio of 7.20 is fine compared to the rest of the industry. URGN outperforms 67.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.47
Quick Ratio	7.2

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.65% over the past year.

The Revenue has grown by 24.01% in the past year. This is a very strong growth!

The Revenue has been growing by 135.99% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)29.65%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25.38%

Revenue 1Y (TTM)24.01%

Revenue growth 3Y91.38%

Revenue growth 5Y135.99%

Sales Q2Q%9.24%

3.2 Future

The Earnings Per Share is expected to grow by 22.32% on average over the next years. This is a very strong growth

Based on estimates for the next years, URGN will show a very strong growth in Revenue. The Revenue will grow by 45.20% on average per year.

EPS Next Y1.66%

EPS Next 2Y9.94%

EPS Next 3Y14.62%

EPS Next 5Y22.32%

Revenue Next Year17.72%

Revenue Next 2Y36.77%

Revenue Next 3Y46.68%

Revenue Next 5Y45.2%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for URGN. In the last year negative earnings were reported.

Also next year URGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as URGN's earnings are expected to grow with 14.62% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.94%

EPS Next 3Y14.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

URGN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

UROGEN PHARMA LTD

NASDAQ:URGN (7/3/2024, 6:41:07 PM)

15.01

-0.13 (-0.86%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap617.36M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.01%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	89.54%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.42

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.47
Quick Ratio	7.2
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)29.65%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y1.66%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)24.01%

Revenue growth 3Y91.38%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

UROGEN PHARMA LTD (URGN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens